CGON logo

CGON CG Oncology Inc.

NASDAQ · Biotechnology · Healthcare

$79.47
-2.43 (-2.97%)

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinica…

Market Cap: $7.10Bcgoncology.com

Price

No data yet.

Social Signal Score

57
5d
73
2 mentions
—
30d
51
7 mentions
—
60d
51
7 mentions
—
90d
53
9 mentions
—
news: 6 · rss: 3

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 0Sell 0Strong Sell 0
Avg price target$106+33.4%
Low $97Median $100High $120
Current Consensus

Revenue

$1.60M
$0.00$774.0K$1.55M$2.32M
Dec 2022Sep 2026

Analyst Estimates

FY2025
$-2.18
$-2.26–$-2.12
11 analysts
FY2026
$-2.99
$-3.16–$-2.88
10 analysts
FY2027
$-3.09
$-4.36–$-1.84
10 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Arthur Kuan
Sector
Healthcare
Industry
Biotechnology
Employees
142
Beta
0.24
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
76.05
cgoncology.com